108 related articles for article (PubMed ID: 16029630)
1. [Association between A49T polymorphism of SRD5A2 gene and risk of prostate cancer].
Tong M; Ai JK; Yuan YM; Yin Y; Zhou LQ; Xin DQ; Li M; Na YQ
Zhonghua Yi Xue Za Zhi; 2005 May; 85(19):1319-21. PubMed ID: 16029630
[TBL] [Abstract][Full Text] [Related]
2. [Association of polymorphisms in testosterone 5-alpha-reductase II genotype and prognosis factors of prostate cancer].
Tong M; Xu Z; Ai JK; Yuan YM; Yin Y; Wang JQ; Li HW; Liu JH; Xin DQ; Zhou LQ; Li M; Na YQ
Zhonghua Wai Ke Za Zhi; 2004 Dec; 42(24):1493-6. PubMed ID: 15733480
[TBL] [Abstract][Full Text] [Related]
3. Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population.
Li Z; Habuchi T; Mitsumori K; Kamoto T; Kinoshitu H; Segawa T; Ogawa O; Kato T
J Urol; 2003 Jun; 169(6):2378-81. PubMed ID: 12771801
[TBL] [Abstract][Full Text] [Related]
4. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
Salam MT; Ursin G; Skinner EC; Dessissa T; Reichardt JK
Urol Oncol; 2005; 23(4):246-53. PubMed ID: 16018939
[TBL] [Abstract][Full Text] [Related]
5. The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population.
Giwercman YL; Abrahamsson PA; Giwercman A; Gadaleanu V; Ahlgren G
Eur Urol; 2005 Oct; 48(4):679-85. PubMed ID: 16039774
[TBL] [Abstract][Full Text] [Related]
6. Association among polymorphisms in the steroid 5alpha-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population.
Paz-y-Miño C; Witte T; Robles P; Llumipanta W; Díaz M; Arévalo M
Cancer Genet Cytogenet; 2009 Mar; 189(2):71-6. PubMed ID: 19215786
[TBL] [Abstract][Full Text] [Related]
7. Association of SRD5A2 genotype and pathological characteristics of prostate tumors.
Jaffe JM; Malkowicz SB; Walker AH; MacBride S; Peschel R; Tomaszewski J; Van Arsdalen K; Wein AJ; Rebbeck TR
Cancer Res; 2000 Mar; 60(6):1626-30. PubMed ID: 10749132
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer.
Chang BL; Zheng SL; Isaacs SD; Turner AR; Bleecker ER; Walsh PC; Meyers DA; Isaacs WB; Xu J
Prostate; 2003 Jun; 56(1):37-44. PubMed ID: 12746845
[TBL] [Abstract][Full Text] [Related]
9. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.
Hsing AW; Chen C; Chokkalingam AP; Gao YT; Dightman DA; Nguyen HT; Deng J; Cheng J; Sesterhenn IA; Mostofi FK; Stanczyk FZ; Reichardt JK
Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1077-82. PubMed ID: 11588134
[TBL] [Abstract][Full Text] [Related]
10. Longer (TA)n repeat but not A49T and V89L polymorphisms in SRD5A2 gene may confer prostate cancer risk in South Indian men.
Rajender S; Vijayalakshmi K; Pooja S; Madhavi S; Paul SF; Vettriselvi V; Shroff S; Singh L; Thangaraj K
J Androl; 2009; 30(6):703-10. PubMed ID: 19443907
[TBL] [Abstract][Full Text] [Related]
11. [V89L polymorphism of the testosterone 5-alpha-reductase II gene and prognostic factors of prostate cancer].
Tong M; Jin YY; Li G; Liu SM; Ji CD
Zhonghua Nan Ke Xue; 2010 Nov; 16(11):990-3. PubMed ID: 21218640
[TBL] [Abstract][Full Text] [Related]
12. The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer.
Scariano JK; Treat E; Alba F; Nelson H; Ness SA; Smith AY
Prostate; 2008 Dec; 68(16):1798-805. PubMed ID: 18780294
[TBL] [Abstract][Full Text] [Related]
13. [Genetic risk factors of prostate cancer in Han nationality population in Northern China and a preliminary study of the reason of racial difference in prevalence of prostate cancer].
Liu JH; Li HW; Tong M; Li M; Na YQ
Zhonghua Yi Xue Za Zhi; 2004 Mar; 84(5):364-8. PubMed ID: 15061984
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in the 5alpha reductase type 2 gene and urologic measures of BPH.
Roberts RO; Bergstralh EJ; Farmer SA; Jacobson DJ; McGree ME; Hebbring SJ; Cunningham JM; Anderson SA; Thibodeau SN; Lieber MM; Jacobsen SJ
Prostate; 2005 Mar; 62(4):380-7. PubMed ID: 15389785
[TBL] [Abstract][Full Text] [Related]
15. A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland.
Mononen N; Ikonen T; Syrjäkoski K; Matikainen M; Schleutker J; Tammela TL; Koivisto PA; Kallioniemi OP
Br J Cancer; 2001 May; 84(10):1344-7. PubMed ID: 11355945
[TBL] [Abstract][Full Text] [Related]
16. The V89L polymorphism in the 5-alpha-reductase type 2 gene and risk of breast cancer.
van Gils CH; Onland-Moret NC; Roest M; van Noord PA; Peeters PH
Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1194-9. PubMed ID: 14652280
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms of GSTM1 and CYP1A1 genes and their genetic susceptibility to prostate cancer in Chinese men.
Li M; Guan TY; Li Y; Na YQ
Chin Med J (Engl); 2008 Feb; 121(4):305-8. PubMed ID: 18304461
[TBL] [Abstract][Full Text] [Related]
18. CYP3A5 gene polymorphism and risk of prostate cancer in a Japanese population.
Zhenhua L; Tsuchiya N; Narita S; Inoue T; Horikawa Y; Kakinuma H; Kato T; Ogawa O; Habuchi T
Cancer Lett; 2005 Jul; 225(2):237-43. PubMed ID: 15876487
[TBL] [Abstract][Full Text] [Related]
19. Increased risk of prostate cancer and benign prostatic hyperplasia associated with transforming growth factor-beta 1 gene polymorphism at codon10.
Li Z; Habuchi T; Tsuchiya N; Mitsumori K; Wang L; Ohyama C; Sato K; Kamoto T; Ogawa O; Kato T
Carcinogenesis; 2004 Feb; 25(2):237-40. PubMed ID: 14604900
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms in the androgen receptor and type II 5 alpha-reductase genes and prostate cancer prognosis.
Shibata A; Garcia MI; Cheng I; Stamey TA; McNeal JE; Brooks JD; Henderson S; Yemoto CE; Peehl DM
Prostate; 2002 Sep; 52(4):269-78. PubMed ID: 12210487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
